Ventripoint Appoints Dr. Samuel Schwartz Chair of Business Advisory Committee

Tickers: XTSX:VPT, PINX:VPTDF
Tags: Heathcare, Technology



Toronto, Ontario / TheNewswire / March 14, 2018 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company", TSXV:VPT) is pleased to announce that it has created a Business Advisory Committee (BAC) and has appointed Dr. Samuel Schwartz as the inaugural Chairman. The BAC will provide senior management and the Board of Directors with strategic advice on matters including, but not limited to, financing alternatives and opportunities, market opportunities, human resource insights, and new technology perspectives, in addition to carrying out special assignments.

"We are very pleased to have Sam's many years of assisting small companies to grow internationally at our disposal," stated Dr. George Adams, CEO of Ventripoint. "This is especially important at this time as the Company looks at strategic approaches to growing its business."

"I am excited to have the opportunity to bring together a world-class group to advise Ventripoint on its goal to achieve better cardiac diagnosis and monitoring for everyone, especially children," commented Dr. Schwartz.

Sam is the founder of The Strategic Law Group. He previously was the Managing Partner of the Toronto office of DLA Piper Canada LLP, where he practiced in the areas of corporate/commercial, corporate finance, structuring, and securities law, including merchant banking and public and private company transactions. His diverse client base included Canadian and foreign companies involved in the life sciences, biotechnology, and computer hardware and software. Sam has regularly assisted established as well as start-up companies in accessing the capital markets both in Canada and the United States. In addition, he has assembled professional teams to assist Canadian companies in their business development efforts worldwide.

Among Sam's community involvements, he served on The Strategic Planning Committee of the Baycrest Centre for Geriatric Care; The National Board of Directors of the Canadian Friends of Hebrew University; The National Campaign Cabinet of the Canadian Cancer Society; and the Board of Directors of Mount Sinai Hospital Foundation. He also served on the Board of Governors of York University and is presently a Life Honorary Governor of the University.

Sam received his JD and LLB from Osgoode Hall Law School of York University and was called to the Ontario Bar in 1974 and the Alberta Bar in 1978. Previously, he received an MA degree from York University and a BA degree from the University of Toronto. In 2010, he was recognized by Osgoode Hall Law School by being awarded a Gold Key for Outstanding Achievement. In 2015, he was awarded an Honorary Doctorate Degree from York University for Outstanding Contributions to the Canadian Community.

About Ventripoint Diagnostics Ltd.

Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.

For further information, please contact:

Dr. George Adams, CEO,

Telephone: (519) 803-6937

Email: gadams@ventripoint.com

Forward Looking Statements:

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright (c) 2018 TheNewswire - All rights reserved.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.